Clinical and biological effects of treatment with amifostine in myelodysplastic syndromes.
We treated six patients with primary myelodysplastic syndrome (MDS) with amifostine (200 mg/m(2) i.v./three times a week for three consecutive weeks). Neutrophil counts were more frequently increased than platelet and reticulocyte counts, but no reduction of the transfusion requirement was observed. Significant reduction of the marrow blasts was observed in one case of refractory anaemia with excess of blasts. In vitro stimulation of haematopoiesis was observed in five cases. The apoptotic rate of marrow cells was significantly diminished even after the first course. Our findings show fairly good clinical and biological response to amifostine in MDS.
Invernizzi
Rosangela
R
Medicina Interna ed Oncologia Medica, Università di Pavia, IRCCS Policlinico S. Matteo, Pavia, Italy. r.invernizzi@smatteo.pv.it
Pecci
Alessandro
A
Travaglino
Erica
E
Gobbi
Paolo G
PG
Malabarba
Lucia
L
Ramajoli
Isabella
I
Ascari
Edoardo
E
D000368:Aged; D004999:Amifostine / Q000627:therapeutic use*; D000975:Antioxidants / Q000627:therapeutic use*; D017209:Apoptosis / Q000187:drug effects; D001854:Bone Marrow Cells / Q000187:drug effects / Q000473:pathology; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D009190:Myelodysplastic Syndromes / Q000097:blood / Q000188:drug therapy* / Q000473:pathology; D009504:Neutrophils / Q000473:pathology; D010976:Platelet Count; D012156:Reticulocytes / Q000473:pathology; D016896:Treatment Outcome
D000975:Antioxidants; D004999:Amifostine